The race for combined checkpoint inhibition in NSCLC

Lancet Oncol. 2016 Mar;17(3):259-260. doi: 10.1016/S1470-2045(15)00580-X. Epub 2016 Feb 6.

Author

Edward B Garon¹

Affiliation

¹ David Geffen School of Medicine at the University of California, Los Angeles, CA 90095, USA. Electronic address: [email protected].

PMID: 26858123
DOI: 10.1016/S1470-2045(15)00580-X

No abstract available

Publication types

Comment

MeSH terms

Carcinoma, Non-Small-Cell Lung*
Humans
Lung Neoplasms*